Translating Antisense Technology into a Treatment for Huntington's Disease.

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Most central nervous system (CNS) diseases lack disease-modifying therapies despite advances in molecular biology and genetics.
• Antisense oligonucleotides (ASOs) are RNA-targeting molecules that can regulate gene expression by reducing protein production.
• Huntington's disease (HD), a dominantly inherited neurodegenerative disorder caused by a CAG repeat expansion in the huntingtin (HTT) gene, is a potential candidate for ASO therapy.

Purpose of the Study:

• To review translational science techniques for developing an antisense oligonucleotide (ASO) therapy targeting huntingtin (HTT) RNA for Huntington's disease (HD).
• To emphasize a data-driven, stepwise approach to ASO drug development for HD, integrating basic, preclinical, and clinical research.

Main Methods:

• Characterizing the natural history and biomarkers of HD.
• Utilizing predictive preclinical models to assess mutant huntingtin protein (Htt) gain-of-function and wild-type Htt loss-of-function.
• Evaluating toxicokinetic and pharmacodynamic effects of ASOs in animal models.
• Developing biomarkers for target engagement and pathological effects, translating from animals to HD patients.
• Establishing reliable CNS drug delivery methods.
• Designing efficient clinical trials for HD ASO therapeutics.

Main Results:

• The review focuses on translational science strategies crucial for efficient and informed ASO development for HD.
• A comprehensive understanding of all drug development phases is essential for successful therapeutic advancement.

Conclusions:

• Translational science provides a framework for developing ASO therapies for Huntington's disease.
• A stepwise, data-driven approach integrating preclinical and clinical research is key to advancing ASO therapeutics for HD.